Attached files
| file | filename |
|---|---|
| EX-99.1 - PDL BIOPHARMA, INC. | v210344_ex99-1.htm |
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of
Report (Date of Earliest Event Reported): February 2,
2011
PDL
BioPharma, Inc.
(Exact
name of Company as specified in its charter)
000-19756
(Commission
File Number)
|
Delaware
|
94-3023969
|
|
|
(State
or Other Jurisdiction of
|
(I.R.S.
Employer Identification No.)
|
|
|
Incorporation)
|
932
Southwood Boulevard
Incline
Village, Nevada 89451
(Address
of principal executive offices, with zip code)
(775)
832-8500
(Company’s
telephone number, including area code)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the Company under any of the following
provisions:
|
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Item
8.01 Other Events.
PDL
BioPharma, Inc. Resolves Patent Disputes with UCB Pharma SA
On
February 7, 2011, PDL BioPharma, Inc. (“PDL”) and UCB SA, on behalf of its
affiliate UCB Pharma S.A. (“UCB”), jointly announced that the companies have
entered into a definitive settlement agreement that resolves all legal disputes
between the parties, including those relating to UCB’s pegylated humanized
antibody fragment, Cimzia®
(certoluzimab pegol), and PDL’s Queen et al. patents.
Under the
terms of the settlement agreement, PDL provided UCB a covenant not to sue UCB
for any royalties regarding UCB’s Cimzia product under the Queen et al. patent
portfolio in return for a lump sum payment of $10 million and the mutual
resolution of other disputes between the two companies, including two pending
patent interference proceedings before the United States Patent and Trademark
Office and a patent opposition in the European Patent Office. No additional
payments will be owed by UCB to PDL under the Queen et al. patent portfolio in
respect of Cimzia sales for any indication and the sale of a product in
development that may or may not be approved within the term of the Queen et al.
patent portfolio.
On
February 7, 2011, PDL issued a press release announcing the above settlement.
The press release is attached hereto as Exhibit 99.1 and is incorporated herein
by reference.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits.
|
Exhibit
No.
|
Description
|
|
|
99.1
|
Press
Release, dated February 7,
2011
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Company has duly
caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
|
PDL
BIOPHARMA, INC.
|
|
|
(Company)
|
|
|
By:
|
/s/ Christopher Stone
|
|
Christopher
Stone
|
|
|
Vice
President, General Counsel and
Secretary
|
|
Dated: February
7, 2011
EXHIBIT
INDEX
|
Exhibit
No.
|
Description
|
|
|
99.1
|
Press
Release, dated February 7,
2011
|